High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy

Oncotarget

Volumn 6, Issue 29, 2015, Pages 28478-28490

  Fu, Xiang ^a,b   Hu, Jiali ^a   Han, Hong Yu ^a   Hua, Yi Jun ^a   Zhou, Ling ^a   Shuai, Wen Di ^a   Du, Wu Ying ^a   Kuang, Chun Mei ^a   Chen, Shuai ^a   Huang, Wenlin ^a,c   Liu, Ran Yi ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Science Park   (China)

Author keywords

chemoradiotherapy; nasopharyngeal carcinoma; platinum resistance; prognostic markers; xeroderma pigmentosum complementation group A

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN A; SMALL INTERFERING RNA; XERODERMA PIGMENTOSUM GROUP A PROTEIN; ANTINEOPLASTIC AGENT; XPA PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CELL ASSAY; CELL STIMULATION; CELLULAR DISTRIBUTION; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IMMUNOHISTOCHEMISTRY; INDUCTION CHEMOTHERAPY; INTERMETHOD COMPARISON; LOW RISK PATIENT; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; CELL SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RADIATION RESPONSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STATISTICS AND NUMERICAL DATA; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 84944463670     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4424     Document Type: Article

References (41)

1. Wei KR, Zheng RS, Zhang SW, Liang ZH, Ou ZX and Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China in 2010. Chin J Cancer. 2014; 33:381- 387.
2. Jia W-H, Huang Q-H, Liao J, Ye W, Shugart YY, Liu Q, Chen L-Z, Li Y-H, Lin X, Wen F-L, Adami H-O, Zeng Y and Zeng Y-X. Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC cancer. 2006; 6:178.
3. Chan AT, Teo PM, Ngan RK, Leung TW, Lau WH, Zee B, Leung SF, Cheung FY, Yeo W, Yiu HH, Yu KH, Chiu KW, Chan DT, Mok T, Yuen KT, Mo F, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002; 20:2038-2044.
4. Langendijk JA, Leemans CR, Buter J, Berkhof J and Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. J Clin Oncol. 2004; 22:4604-4612.
5. Baujat B, Audry H, Bourhis J, Chan ATC, Onat H, Chua DTT, Kwong DLW, al-Sarraf M, Chi K-H, Hareyama M, Leung SF, Thephamongkhol K and Pignon J-P. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006; 64:47-56.
6. Zhang A-M, Fan Y, Wang X-X, Xie Q-C, Sun J-G, Chen Z-T and Zhu B. Increased treatment-related mortality with additional cisplatin-based chemotherapy in patients with nasopharyngeal carcinoma treated with standard radiotherapy. Radiother Oncol. 2012; 104:279-285.
7. Liu RY, Dong Z, Liu J, Yin JY, Zhou L, Wu X, Yang Y, Mo W, Huang W, Khoo SK, Chen J, Petillo D, Teh BT, Qian CN and Zhang JT. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma. Oncogene. 2011; 30:4814-4823.
8. Riedl T, Hanaoka F and Egly JM. The comings and goings of nucleotide excision repair factors on damaged DNA. EMBO J. 2003; 22:5293-5303.
9. Martin LP, Hamilton TC and Schilder RJ. Platinum Resistance: The Role of DNA Repair Pathways. Clin Cancer Res. 2008; 14:1291-1295.
10. Bowden NA. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer lett. 2014; 346:163-171.
11. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA and Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol cancer. 2005; 4:18.
12. Liu Y, Bernauer AM, Yingling CM and Belinsky SA. HIF1 regulated expression of XPA contributes to cisplatin resistance in lung cancer. Carcinogenesis. 2012; 33:1187- 1192.
13. Wu X, Fan W, Xu S and Zhou Y. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res. 2003; 9:5874-5879.
14. Cummings M, Higginbottom K, McGurk CJ, Wong OGW, Köberle B, Oliver RTD and Masters JR. XPA versus ERCC1 as chemosensitising agents to cisplatin and mitomycin C in prostate cancer cells: Role of ERCC1 in homologous recombination repair. Biochem Pharmacol. 2006; 72:166-175.
15. Rosenberg E, Taher MM, Kuemmerle NB, Farnsworth J and Valerie K. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin. Cancer Res. 2001; 61:764-770.
16. Köberle B, Roginskaya V, Zima KS, Masters JRW and Wood RD. Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation. Mol Carcinog. 2008; 47:580-586.
17. Stevens EV, Raffeld M, Espina V, Kristensen GB, Trope CG, Kohn EC and Davidson B. Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005; 103:2313- 2319.
18. Ganzinelli M, Mariani P, Cattaneo D, Fossati R, Fruscio R, Corso S, Ricci F, Broggini M and Damia G. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. Eur J Cancer. 2011; 47:1086-1094.
19. Mendoza J, Martinez J, Hernandez C, Perez-Montiel D, Castro C, Fabian-Morales E, Santibanez M, Gonzalez-Barrios R, Diaz-Chavez J, Andonegui MA, Reynoso N, Onate LF, Jimenez MA, Nunez M, Dyer R and Herrera LA. Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours. Br J Cancer. 2013; 109:68-75.
20. Rosenberg B, Vancamp L and Krigas T. Inhibition of cell division in Escherichia Coli by Electrolysis products from a Platinum Electrode. Nature. 1965; 205:698-699.
21. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340:1144-1153.
22. Wang D and Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4:307-320.
23. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2011; 31:1869-1883.
24. Ishida S, Lee J, Thiele DJ and Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99:14298-14302.
25. Morimoto A, Serada S, Enomoto T, Kim A, Matsuzaki S, Takahashi T, Ueda Y, Yoshino K, Fujita M, Fujimoto M, Kimura T and Naka T. Annexin A4 induces platinum resistance in a chloride-and calcium-dependent manner. Oncotarget. 2014; 5:7776-7787.
26. Mistry P, Kelland LR, Abel G, Sidhar S and Harrap KR. The relationships between glutathione, glutathione- S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 1991; 64:215-220.
27. Wang Q, Shi S, He W, Padilla MT, Zhang L, Wang X, Zhang B and Lin Y. Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget. 2014; 5:1304-1314.
28. Shen DW, Pouliot LM, Hall MD and Gottesman MM. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacol Rev. 2012; 64:706-721.
29. Liu RY, Dong Z, Liu J, Zhou L, Huang W, Khoo SK, Zhang Z, Petillo D, Teh BT, Qian CN and Zhang JT. Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells. Mol Cancer Ther. 2013; 12:2157-2166.
30. Lai TC, Chow KC, Fang HY, Cho HC, Chen CY, Lin TY, Chiang IP and Ho SP. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients. Oncol Rep. 2011; 25:1243-1251.
31. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH and Park K. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008; 99:167-172.
32. Hsu DS, Lan HY, Huang CH, Tai SK, Chang SY, Tsai TL, Chang CC, Tzeng CH, Wu KJ, Kao JY and Yang MH. Regulation of excision repair cross-complementation group by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16:4561-4571.
33. Huang PY, Li Y, Mai HQ, Luo RZ, Cai YC and Zhang L. Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncol. 2012; 48(10):964-968.
34. Ding D, Zhang Y, Yu H, Guo Y, Jiang L, He X, Ma W and Zheng W. Genetic variation of XPA gene and risk of cancer: A systematic review and pooled analysis. Int J Cancer. 2012; 131:488-496.
35. Butkiewicz D, Drosik A, Suwinski R, Krzesniak M, Rusin M, Kosarewicz A, Rachtan J, Matuszczyk I and Gawkowska-Suwinska M. Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinumbased chemotherapy. Int J Cancer. 2012; 131:E1100-E1108.
36. Chan KC. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma. Chin J Cancer. 2014; 33:598-603.
37. Young LS and Dawson CW. Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014; 33:581- 590.
38. Yu H, Ye W, Wu J, Meng X, Liu RY, Ying X, Zhou Y, Wang H, Pan C and Huang W. Overexpression of sirt7 exhibits oncogenic property and serves as a prognostic factor in colorectal cancer. Clin Cancer Res. 2014; 20:3434- 3445.
39. Biard DSF. Untangling the relationships between DNA repair pathways by silencing more than 20 DNA repair genes in human stable clones. Nucleic Acids Res. 2007; 35:3535-3550.
40. Chen H, Gao S, Liu J, Li D, Sheng C, Yao C, Jiang W, Wu J, Chen S and Huang W. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2- dependent cancer. Oncotarget. 2015 Apr 12. [Epub ahead of print].
41. Zhou Y, Wu J, Fu X, Du W, Zhou L, Meng X, Yu H, Lin J, Ye W, Liu J, Peng H, Liu RY, Pan C and Huang W. OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer. Mol Cancer. 2014; 13:258.